---
title: "Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial | XAIR Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279487624.md"
description: "Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial | XAIR Stock News"
datetime: "2026-03-17T12:35:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279487624.md)
  - [en](https://longbridge.com/en/news/279487624.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279487624.md)
---

# Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial | XAIR Stock News

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial | XAIR Stock News

### Related Stocks

- [XAIR.US](https://longbridge.com/en/quote/XAIR.US.md)

## Related News & Research

- [Merck's uterine cancer drug meets late-stage trial goals](https://longbridge.com/en/news/286758788.md)
- [13:19 ETCancerCheck and Evexia Partner to Make Early, Accurate Cancer Detection a Reality](https://longbridge.com/en/news/286448727.md)
- [Nanobiotix reports 85.7% ORR in phase 2 CONVERGE lung cancer safety lead-in data](https://longbridge.com/en/news/287118634.md)
- [Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer | VCYT Stock News](https://longbridge.com/en/news/286573972.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)